Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
RT @HHS_ASH: The science is clear: Vaccination is safe, and the BEST protection against measles. #VaccinesWork
SteveFDA (R-D.C.)
@SGottliebFDA
Drug Pricing: We’re focused in 2019 on steps to make it more efficient for new generics to launch after approval; including action to reduce manufacturing costs, make scale up of manufacturing and line changes less costly. Bottom line: We want to lower barriers to generic entry. https://t.co/t6szB1EG8G
SteveFDA (R-D.C.)
@SGottliebFDA
FDA finalizes guidance on public recall warnings - POLITICO https://t.co/1Q49WcRtH5
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAOncology: #FDAOncology invites in person and online participants for the March 15, 2019 FDA Oncology Center of Excellence Chi… https://t.co/Eggicbm2Kp
SteveFDA (R-D.C.)
@SGottliebFDA
RT @DrugStoreNews: The @US_FDA has unveiled a new pilot project in which manufacturers, repackagers and other stakeholders can pilot t… https://t.co/Kp3tkTitB7
SteveFDA (R-D.C.)
@SGottliebFDA
Spotted in Bloomberg’s kitchen today before my TV hit: A food manufacturing facility. No inspection history on file with FDA https://t.co/e8EWSNZa3T
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDADeviceInfo: #ICYMI: Read the statement from Binita Ashar, M.D., of @US_FDA 's Center for Devices and Radiological Health on th… https://t.co/guapeetJS9
SteveFDA (R-D.C.)
@SGottliebFDA
RT @ASCO: Read the exclusive interview between @CliffordHudis and @SGottliebFDA on how innovative technology demands new regu… https://t.co/0cErmmFvuz
SteveFDA (R-D.C.)
@SGottliebFDA
RT @GDAFoodSafety: RT @FrankYiannasFDA: “We’re committed to staying at the forefront of new & emerging technologies...to create safer,… https://t.co/9ijP9L6C6a
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: One of the most troubling public health issues today is the escalating popularity of e-cigarettes among our nation’… https://t.co/dJhsBbpIf7
SteveFDA (R-D.C.)
@SGottliebFDA
RT @KBDeSalvo: Great work by you and the @ONC_HealthIT team Don! Thanks for the bold moves to empower people with their data! @Policy2Prog… QT @donrucker: Finally! @ONC_HealthIT interoperability proposed rule is out. Getting American patients their medical chart on thei… https://t.co/SW8WNPUkCg)
SteveFDA (R-D.C.)
@SGottliebFDA
We’re committed to helping beneficial products and innovation advance in the dietary supplement space; but to protect consumers from a small number of bad actors in this burgeoning industry, we need to modernize our framework for overseeing these products: https://t.co/RLVVrZODOA
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAMedia: Statement from FDA Commissioner @SGottliebFDA, on the agency’s new efforts to strengthen regulation of dietary supp… https://t.co/wGJYrV2DEE
SteveFDA (R-D.C.)
@SGottliebFDA
RT @NYTHealth: The F.D.A. warns dietary supplement sellers to stop claiming their powders and pills can cure Alzheimer's and other… https://t.co/NC0tTalP5I
SteveFDA (R-D.C.)
@SGottliebFDA
RT @TomBurtonWSJ: Easing access to your health records: Proposed federal rules could bolster efforts to bring information such as ins… https://t.co/gCxTpNwvth
SteveFDA (R-D.C.)
@SGottliebFDA
RT @Surgeon_General: We must protect our nation’s young people from a lifetime of nicotine addiction and associated problems by immediat… https://t.co/jxnpMRMbYV
SteveFDA (R-D.C.)
@SGottliebFDA
In the fight against illicit opioid flows FDA has taken new action to step up our enforcement in international mail facilities and our oversight of illegal internet sales. Now we’re focusing new efforts on illegal diversion from the legitimate supply chain https://t.co/kVv8LMrjIj
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAMedia: Statement from FDA Commissioner @SGottliebFDA and Deputy Commissioner Frank Yiannas on findings from the agency’s i… https://t.co/duEd1v1POi
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDATobacco: .@US_FDA @CDCgov and @theNCI analyzed data from the 2011–2018 National Youth Tobacco Surveys (NYTS) to determine cu… https://t.co/nweqxhySKz
SteveFDA (R-D.C.)
@SGottliebFDA
Check out today’s perspective in @NEJM from @FDAOncology authors on a major breast cancer trial; considerations for drug development in patients with residual disease, after neoadjuvant therapy, an unmet medical need: https://t.co/mgb2IhKT6T